Effect of Ketoconazole on the Pharmacokinetic Profile of Buprenorphine following Administration of a Once-Weekly Buprenorphine Transdermal System

被引：0
作者：
Ram P. Kapil
Alessandra Cipriano
Gregory H. Michels
Peter Perrino
Sarah A. O’Keefe
Manjunath S. Shet
Salvatore V. Colucci
Robert J. Noveck
Stephen C. Harris
机构：
[1] Purdue Pharma L.P.,
[2] Duke University School of Medicine,undefined
来源：
Clinical Drug Investigation | 2012年 / 32卷 / 9期
关键词：
Ketoconazole; Buprenorphine; CYP3A4 Inhibition; Application Site Reaction; BTDS;
D O I：
10.1007/BF03261913
中图分类号：
学科分类号：
摘要：
Background and Objective: Buprenorphine is extensively metabolized by cytochrome P450 (CYP) 3A4. This study evaluated the effect of ketoconazole, a CYP3A4 inhibitor, on the metabolism of buprenorphine following the administration of a buprenorphine transdermal system 10μg/hour (BTDS 10).
引用
收藏
页码：583 / 592
页数：9
相关论文
共 71 条
[1]  
Ohtani M.(2007)Basic pharmacology of buprenorphine Eur J Pain Suppl. 1 69-73
[2]  
Huang P.(2001)Comparison of pharmacological activities of buprenorphine and norbu-prenorphine: norbuprenorphine is a potent opioid agonist J Pharmacol Exp Ther 297 688-95
[3]  
Kehner G.B.(2007)Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther Drug Monit 29 687-710
[4]  
Cowan A.(2005)Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes Biol Pharm Bull 28 1805-8
[5]  
Zhou S.-F.(2009)Inhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazole Br J Clin Pharmacol 68 712-20
[6]  
Xue C.C.(2009)The need for multiple doses of 400 mg ketoconazole as a precipitant inhibitor of a CYP3A substrate in an in vivo drug-drug interaction study [letter J Clin Pharmacol 49 368-9
[7]  
Yu X.-Q.(1994)Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells J Urol 151 485-91
[8]  
Niwa T.(2001)Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for 7 days J Clin Pharmacol 41 1026-304
[9]  
Shiraga T.(2007)Drug interaction studies: study design, data analysis, and implications for dosing and labeling Clin Pharmacol Ther 81 298-9
[10]  
Takagi A.(2009)Quantitative evaluation of pharmacokinetic inhibition of CYP3A substrates by ketoconazole: a simulation study J Clin Pharmacol 49 351-9
12345678